Deferoxamine-DBCO

Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors[1][2][3].

Product Specifications

CAS Number

[2359695-48-8]

Product Name Alternative

DFO-DBCO

UNSPSC

12352200

Target

Biochemical Assay Reagents; Radionuclide-Drug Conjugates (RDCs)

Type

Biochemical Assay Reagents

Related Pathways

Antibody-drug Conjugate/ADC Related; Others

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/deferoxamine-dbco.html

Purity

94.38

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N1CC2=C(C=CC=C2)C#CC3=C1C=CC=C3)=O)=O)O)=O)=O)O)=O)=O)O)=O

Molecular Formula

C44H61N7O10

Molecular Weight

848.00

References & Citations

[1]Sales ZS, et al. Practical syntheses of DOTAGA-DBCO and DFO-DBCO, strained alkyne pre-cursors to radioimmunoconjugates for targeted alpha therapy. Bioorg Med Chem. 2022 Nov 1;73:117010. |[2]Hofstraat SRJ, et al. Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Nat Nanotechnol. 2025 Apr;20 (4) :532-542. |[3]Huang F Y J, et al. Preparation and Characterization of Site-Specifically Radiolabeled 89Zr-DFO-anti-PD-L1-mAb ImmunoPET Tracer[J]. 2023.